STOCK TITAN

SAB Biotherapeutics: Woodline reports 5.7% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. (SABS) is the issuer whose common stock Woodline Partners LP reports beneficially owning 5,455,694 shares, or 5.7% of the class. The amount includes 1,180,694 common shares, 2,850,000 shares issuable upon conversion of Series B preferred stock underlying 28,500 Enrollment Warrants, and 1,425,000 shares issuable upon conversion of Series B preferred stock underlying 14,250 Data Release Warrants.

Woodline Partners is the investment adviser to Woodline Master Fund LP, which directly holds the securities and has the right to receive dividends or sale proceeds. The 5.7% calculation uses 90,986,368 common shares outstanding as of August 3, 2026, and assumes conversion of the preferred stock issuable upon exercise of the warrants. Woodline reports sole voting and dispositive power over the beneficially owned amount.

Beneficially owned 5,455,694 shares SAB Biotherapeutics common stock, including shares issuable upon conversion
Reported ownership percentage 5.7% Calculated using 90,986,368 common shares outstanding as of August 3, 2026, and assuming conversion of preferred stock issuable upon warrant exercise
Common shares outstanding 90,986,368 shares As of August 3, 2026
Common shares held 1,180,694 shares Common shares included in Woodline Partners’ reported beneficial ownership
Shares issuable upon conversion—Enrollment Warrants 2,850,000 shares Series B preferred stock underlying 28,500 Enrollment Warrants
Shares issuable upon conversion—Data Release Warrants 1,425,000 shares Series B preferred stock underlying 14,250 Data Release Warrants
beneficially owned financial
"Amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Series B Preferred Stock financial
"shares of Series B Preferred Stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Enrollment Warrants financial
"underlying 28,500 Enrollment Warrants"
Data Release Warrants financial
"underlying 14,250 Data Release Warrants"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SABS shares does Woodline Partners report beneficially owning?

Woodline Partners LP reports beneficial ownership of 5,455,694 shares of SABS common stock, or 5.7% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





78397T202

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of (i) 1,180,694 shares of Common Stock (as defined in Item 2(a)), (ii) 2,850,000 shares of Common Stock issuable upon conversion of 28,500 shares of Series B preferred stock (the "Series B Preferred Stock") underlying 28,500 enrollment warrants (the "Enrollment Warrants") and (iii) 1,425,000 shares of Common Stock issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants").


SCHEDULE 13G



Woodline Partners LP
Signature:/s/ Erin Mullen
Name/Title:Erin Mullen, General Counsel & Chief Compliance Officer
Date:11/16/2026

Keep reading